Premium
Etanercept as prophylactic psoriatic therapy before interferon‐α and ribavirin treatment for active hepatitis C infection
Author(s) -
Behnam S. E.,
Hindiyeh R.,
Fife D. J.,
Jeffes E. W.,
Wu J. J.
Publication year - 2010
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2009.03476.x
Subject(s) - medicine , psoriasis , ribavirin , etanercept , acitretin , methotrexate , hepatitis c virus , hepatitis c , dermatology , interferon , immunology , ustekinumab , pegylated interferon , adalimumab , virus , tumor necrosis factor alpha
Summary Patients with psoriasis and chronic hepatitis C virus (HCV) infection are a therapeutic challenge. Systemic psoriasis treatment with methotrexate and acitretin can be hepatotoxic, and interferon (IFN)‐α for treatment of HCV can worsen psoriasis. Etanercept can be successfully used in patients with psoriasis and HCV. To our knowledge, this is the first case report of etanercept used prophylactically to prevent a psoriatic flare in a patient with HCV treated with IFN‐α and ribavirin.